Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms

NCT00097942 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT00097942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00097942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms
Lead sponsor
Forest Laboratories
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2004
Completion date
September 30, 2005
Enrollment
138 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia